SV2009003367A - Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct - Google Patents
Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpctInfo
- Publication number
- SV2009003367A SV2009003367A SV2009003367A SV2009003367A SV2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A SV 2009003367 A SV2009003367 A SV 2009003367A
- Authority
- SV
- El Salvador
- Prior art keywords
- archostrosystosis
- archostrosythosis
- arthritis
- compounds
- chronicacrics
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000003252 repetitive effect Effects 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345307P | 2007-03-07 | 2007-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2009003367A true SV2009003367A (es) | 2010-08-10 |
Family
ID=39535719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2009003367A SV2009003367A (es) | 2007-03-07 | 2009-09-07 | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7846953B2 (enExample) |
| EP (1) | EP2129668A1 (enExample) |
| JP (1) | JP2010520306A (enExample) |
| KR (1) | KR20090127410A (enExample) |
| CN (1) | CN101679322A (enExample) |
| AR (1) | AR065655A1 (enExample) |
| AU (1) | AU2008222745A1 (enExample) |
| BR (1) | BRPI0808445A2 (enExample) |
| CA (1) | CA2679944A1 (enExample) |
| CL (1) | CL2008000670A1 (enExample) |
| CO (1) | CO6231008A2 (enExample) |
| EA (1) | EA200970837A1 (enExample) |
| EC (1) | ECSP099614A (enExample) |
| IL (1) | IL200757A0 (enExample) |
| MX (1) | MX2009009517A (enExample) |
| NI (1) | NI200900163A (enExample) |
| NZ (1) | NZ579372A (enExample) |
| SV (1) | SV2009003367A (enExample) |
| TW (1) | TW200902508A (enExample) |
| UA (1) | UA98485C2 (enExample) |
| WO (1) | WO2008109727A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| CA2679944A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| WO2009033703A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| TWI475995B (zh) | 2007-09-14 | 2015-03-11 | 詹森藥物公司 | １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物 |
| PL2200985T3 (pl) | 2007-09-14 | 2011-12-30 | Ortho Mcneil Janssen Pharmaceuticals Inc | 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony |
| RU2492170C9 (ru) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| MX2011003691A (es) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. |
| RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
| KR101172638B1 (ko) * | 2008-12-30 | 2012-08-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| US8729239B2 (en) | 2009-04-09 | 2014-05-20 | Nuclea Biotechnologies, Inc. | Antibodies against fatty acid synthase |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| AR076859A1 (es) | 2009-05-12 | 2011-07-13 | Ortho Mcneil Janssen Pharm | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
| DK2433124T3 (en) * | 2009-05-19 | 2017-06-19 | Vivia Biotech Sl | PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS |
| WO2011019558A1 (en) * | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
| WO2011019556A1 (en) * | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND |
| US8685891B2 (en) | 2009-08-27 | 2014-04-01 | Nuclea Biotechnologies, Inc. | Method and assay for determining FAS expression |
| CN102638980A (zh) * | 2009-10-09 | 2012-08-15 | 俄亥俄州州立大学研究基金会 | 噻唑烷二酮能量限制拟似剂 |
| CN103108634B (zh) * | 2010-07-28 | 2015-08-12 | 幽兰化学医药有限公司 | 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物 |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| ES2390303B1 (es) * | 2011-04-11 | 2013-09-16 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple. |
| WO2012140300A1 (es) * | 2011-04-11 | 2012-10-18 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple |
| USD688465S1 (en) | 2011-06-14 | 2013-08-27 | Telebrands Corp. | Hair detangler |
| US8772277B2 (en) | 2011-08-04 | 2014-07-08 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2013238126C1 (en) | 2012-03-26 | 2018-06-14 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| JP6527822B2 (ja) | 2013-09-25 | 2019-06-05 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 |
| CN109999025A (zh) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| JP6891118B2 (ja) | 2014-12-23 | 2021-06-18 | インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ | 経皮投与のための方法及び製剤 |
| MX2018005340A (es) | 2015-11-02 | 2018-05-17 | Univ Yale | Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos. |
| WO2019055880A2 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | METHOD OF ADMINISTRATION AND TREATMENT |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20220029719A (ko) * | 2019-07-04 | 2022-03-08 | 리드 파마 홀딩 비.브이. | 에스트로겐-관련 수용체 알파 조절제 |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
| JP7629912B2 (ja) * | 2019-10-18 | 2025-02-14 | リード ファーマ ホールディング ビー．ブイ． | エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| BRPI0513367A (pt) | 2004-07-14 | 2008-05-06 | Janssen Pharmaceutica Nv | arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio |
| JP4931824B2 (ja) | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
| CA2679944A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| BRPI0808662B8 (pt) * | 2007-03-07 | 2021-05-25 | Janssen Pharmaceutica Nv | tiazolidinadiona n-alquiladas de fenóxi substituída, seu uso, composição farmacêutica que as compreende e processo para preparar a referida composição farmacêutica |
-
2008
- 2008-03-06 CA CA002679944A patent/CA2679944A1/en not_active Abandoned
- 2008-03-06 UA UAA200910123A patent/UA98485C2/ru unknown
- 2008-03-06 EP EP08731504A patent/EP2129668A1/en not_active Ceased
- 2008-03-06 AU AU2008222745A patent/AU2008222745A1/en not_active Abandoned
- 2008-03-06 US US12/043,269 patent/US7846953B2/en not_active Expired - Fee Related
- 2008-03-06 EA EA200970837A patent/EA200970837A1/ru unknown
- 2008-03-06 TW TW097107941A patent/TW200902508A/zh unknown
- 2008-03-06 BR BRPI0808445-9A patent/BRPI0808445A2/pt not_active IP Right Cessation
- 2008-03-06 WO PCT/US2008/056004 patent/WO2008109727A1/en not_active Ceased
- 2008-03-06 MX MX2009009517A patent/MX2009009517A/es active IP Right Grant
- 2008-03-06 NZ NZ579372A patent/NZ579372A/en not_active IP Right Cessation
- 2008-03-06 JP JP2009552881A patent/JP2010520306A/ja active Pending
- 2008-03-06 CL CL2008000670A patent/CL2008000670A1/es unknown
- 2008-03-06 KR KR1020097020449A patent/KR20090127410A/ko not_active Withdrawn
- 2008-03-06 CN CN200880015196A patent/CN101679322A/zh active Pending
- 2008-03-07 AR ARP080100962A patent/AR065655A1/es not_active Application Discontinuation
-
2009
- 2009-09-04 NI NI200900163A patent/NI200900163A/es unknown
- 2009-09-06 IL IL200757A patent/IL200757A0/en unknown
- 2009-09-07 EC EC2009009614A patent/ECSP099614A/es unknown
- 2009-09-07 SV SV2009003367A patent/SV2009003367A/es unknown
- 2009-09-11 CO CO09097934A patent/CO6231008A2/es not_active Application Discontinuation
-
2010
- 2010-10-07 US US12/899,812 patent/US8344009B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008109727A8 (en) | 2009-12-17 |
| CO6231008A2 (es) | 2010-12-20 |
| ECSP099614A (es) | 2009-10-30 |
| UA98485C2 (ru) | 2012-05-25 |
| AR065655A1 (es) | 2009-06-24 |
| WO2008109727A1 (en) | 2008-09-12 |
| NZ579372A (en) | 2012-02-24 |
| US7846953B2 (en) | 2010-12-07 |
| BRPI0808445A2 (pt) | 2014-08-05 |
| EA200970837A1 (ru) | 2010-04-30 |
| CL2008000670A1 (es) | 2008-11-03 |
| AU2008222745A1 (en) | 2008-09-12 |
| JP2010520306A (ja) | 2010-06-10 |
| KR20090127410A (ko) | 2009-12-11 |
| EP2129668A1 (en) | 2009-12-09 |
| US8344009B2 (en) | 2013-01-01 |
| IL200757A0 (en) | 2010-05-17 |
| CA2679944A1 (en) | 2008-09-12 |
| US20110237625A1 (en) | 2011-09-29 |
| TW200902508A (en) | 2009-01-16 |
| NI200900163A (es) | 2010-07-22 |
| MX2009009517A (es) | 2009-09-16 |
| US20090111855A1 (en) | 2009-04-30 |
| CN101679322A (zh) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003367A (es) | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionados con el estrogeno ref. prd2796svpct | |
| LTPA2020539I1 (lt) | 1'-Pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui | |
| CO6270312A2 (es) | Moduladores de gpr40 bifenilo-sustituidos | |
| CR20110077A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| HN2011002933A (es) | Inhibidores del canal de potasio medular externo renal | |
| AR065657A1 (es) | DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. | |
| CO6341577A2 (es) | Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos | |
| NI200900148A (es) | COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A | |
| AR065656A1 (es) | Tiazolidindionas n-alquiladas fenoxi sustituidas como moduladoras del receptor alfa relacionado con estrogeno | |
| PA8799401A1 (es) | Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas | |
| GT201400102A (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CL2008000430A1 (es) | Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a | |
| AR080207A1 (es) | Aminotiazolonas como modulares de los receptores de estrogenos alfa | |
| CL2007001022A1 (es) | Compuestos derivados de 1h-indol-2-carboxamida; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de h3 tal como obesidad, diabetes tipo ii y | |
| PA8853001A1 (es) | 4-azentidinil-1-heteroaril-ciclohexanol antagonista del ccr2 | |
| CR20110011A (es) | Sustratos que tienen formulaciones con transferibilidad mejorada. | |
| CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac | |
| CL2006003737A1 (es) | Uso de compuestos derivados de triazina o pirimidina sustituida, para tratar o prevenir enfermedades mediadas por los receptores de prokineticina 2 tales como trastornos gastrointestinales. | |
| UY31117A1 (es) | Productos extruidos con enmascaramiento del sabor mejorado | |
| ECSP055985A (es) | Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis | |
| BR112015010207A2 (pt) | método para promover o crescimento de plantas | |
| AR080206A1 (es) | Aminotiazolonas como moduladores del receptor alfa relacionados con estrogeno | |
| UY29962A1 (es) | Compuestos calciliticos | |
| UY31033A1 (es) | Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal | |
| EP2285787A4 (en) | 3-SUBSTITUTED PROPANAMINE COMPOUNDS |